Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma-Reference-Cited by-同舟云学术

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Published:2020-10-23 Issue:3 Volume:113 Page:370-380
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Izutsu Koji^ORCID,Yamamoto Kazuhito,Kato Koji,Ishikawa Takayuki,Fukuhara Noriko,Terui Yasuhito,Choi Ilseung,Humphrey Kathryn,Kim Su Young,Okubo Sumiko,Ogawa Natsumi,Nishimura Yasuko,Salem Ahmed Hamed,Maruyama Dai

Funder

AbbVie

Genentech

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-020-03024-3.pdf

Reference38 articles.

1. O’Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995;85(2):307–18.

2. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536–45.